endolinx Medical News

Endocrinology

Become a Member Today!

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Endocrinology

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Endocrinology

Adrenal Glands

Atherosclerosis/Lipids

Basic Science/Genetics

Bone Metabolism

Diabetes

Diagnostics

Economics of Medicine

Endocrine Oncology

Fetal Development

Hypertension

Metabolism and Growth

Neuroendocrinology

Obesity

Pediatric Endocrinology

Pharmacology/kinetics

Popular Press

Primary Care

Reproductive
Endocrinology

Thyroid/Parathyroid

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

FDA Update: Thyrotropin Approved For Thyroid Cancer Ablation
Tracy Hampton, PhD, MDLinx Oncology

See all

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Cabergoline and the risk of valvular lesions in endocrine disease
European Journal of Endocrinology, 06/25/08

Email This Article

Save in My Library

Free Abstract

Lancellotti P et al. - No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor